Eledon Pharma Analyst Ratings
Eledon Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 669.23% | Noble Capital Markets | → $10 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 592.31% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 05/26/2023 | 1823.08% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 06/01/2022 | 1900% | SVB Leerink | $33 → $26 | Maintains | Outperform |
| 11/24/2021 | 1823.08% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 04/27/2021 | 2438.46% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 03/23/2021 | 1823.08% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 02/08/2021 | 2515.38% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/27/2023 | 669.23% | 来宝资本市场 | →$10 | 开始承保 | →跑赢大盘 |
| 2023年08月22日 | 592.31% | 康托·菲茨杰拉德 | →$9 | 重申 | 超重→超重 |
| 2023年05月26日 | 1823.08% | HC Wainwright公司 | →$25 | 重申 | 购买→购买 |
| 06/01/2022 | 1900% | SVB Leerink | $33→$26 | 维护 | 跑赢大盘 |
| 2021年11月24日 | 1823.08% | HC Wainwright公司 | $35→$25 | 维护 | 买 |
| 04/27/2021 | 2438.46% | SVB Leerink | $34→$33 | 维护 | 跑赢大盘 |
| 03/23/2021 | 1823.08% | 康托·菲茨杰拉德 | →$25 | 开始承保 | →超重 |
| 02/08/2021 | 2515.38% | SVB Leerink | →$34 | 开始承保 | →跑赢大盘 |
What is the target price for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的目标价是多少？
The latest price target for Eledon Pharma (NASDAQ: ELDN) was reported by Noble Capital Markets on September 27, 2023. The analyst firm set a price target for $10.00 expecting ELDN to rise to within 12 months (a possible 669.23% upside). 3 analyst firms have reported ratings in the last year.
来宝资本市场于2023年9月27日报道了Eledon Pharma(纳斯达克：ELDN)的最新目标价。这家分析公司将目标价定为10美元，预计ELDN将在12个月内上涨至(可能上涨669.23%)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的最新分析师评级是多少？
The latest analyst rating for Eledon Pharma (NASDAQ: ELDN) was provided by Noble Capital Markets, and Eledon Pharma initiated their outperform rating.
来宝资本市场对Eledon Pharma(纳斯达克代码：ELDN)的最新分析师评级是由Eledon Pharma发起的表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eledon Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eledon Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Eledon Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对Eledon Pharma的最后一次评级是在2023年9月27日提交的，所以你应该预计下一次评级将在2024年9月27日左右的某个时候公布。
Is the Analyst Rating Eledon Pharma (ELDN) correct?
分析师对Eledon Pharma(ELDN)的评级正确吗？
While ratings are subjective and will change, the latest Eledon Pharma (ELDN) rating was a initiated with a price target of $0.00 to $10.00. The current price Eledon Pharma (ELDN) is trading at is $1.30, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Eledon Pharma(ELDN)评级是以0.00美元至10.00美元的目标价启动的。Eledon Pharma目前的交易价格为1.30美元，在分析师的预测范围内。